TCGA-P3-A6SX-01A-11R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.326484018
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.370
- G2M_CHECKPOINT+0.320
- MYC_TARGETS_V1+0.310
- MYC_TARGETS_V2+0.300
- E2F_TARGETS+0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
- PANCREAS_BETA_CELLS+0.220
- HYPOXIA+0.200
- DNA_REPAIR+0.190
- GLYCOLYSIS+0.140
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.560
- INTERFERON_ALPHA_RESPONSE-0.540
- ALLOGRAFT_REJECTION-0.500
- INFLAMMATORY_RESPONSE-0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
- APOPTOSIS-0.370
- COMPLEMENT-0.360
- TNFA_SIGNALING_VIA_NFKB-0.340
- IL6_JAK_STAT3_SIGNALING-0.280
- KRAS_SIGNALING_UP-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AG0M-TTM1-A-2-1-R-A743-41 | — | A | 0.826 |
| 2 | MNG488 | — | — | 0.826 |
| 3 | SRR8518375 | — | A | 0.826 |
| 4 | BS_1QXEC43H | medulloblastoma | — | 0.821 |
| 5 | SRR2016936 | — | — | 0.818 |
| 6 | C3L-00445 | — | cohortSQ2 | 0.814 |
| 7 | TCGA-FJ-A871-01A-11R-A352-07 | — | — | 0.807 |
| 8 | de19e3c1-3508-4c13-b2cf-7079ee934a55 | — | — | 0.806 |
| 9 | 20ed86b0-2e3d-44ec-88cd-eac5486fe15c | — | — | 0.802 |
| 10 | BS_K81DR8XG | medulloblastoma | — | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.130 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.070 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.010 | Inavolisib | — uncovered |